Skip to main content
. 2018 Jul 5;7:F1000 Faculty Rev-1011. [Version 1] doi: 10.12688/f1000research.14821.1

Table 9. Challenges and recommendations for National TB Programmes.

Category Challenges Proposed remedies
End TB Milestones/Targets on TB
incidence and mortality
Presented globally as percentage reductions
compared with 2015
Change percentage reductions into absolute
“national” numbers against which to measure
progress and present them for all levels of the
health system
Optimize prompt and accurate
diagnosis of TB
Inefficient use of smear microscopy and
Xpert MTB/RIF
Develop algorithms for best use of smear
microscopy/Xpert MTB/RIF; monitor numbers
being screened, tests done, and results; monitor
operational capacity of MTB/RIF instruments;
keep abreast of new diagnostic molecular
technology
Provide rapid, complete, and
effective treatment to all those
diagnosed with TB
Poor linkage of diagnosis and treatment;
wrong denominator for measuring treatment
outcomes; high rates of “not evaluated”
Monitor and improve linkage to care; use
diagnosed TB patients as the denominator for
treatment outcomes; obtain treatment outcomes
for transfer-out patients
Implement and monitor
effective infection control
practices for MTB
Poor infection control practices and
monitoring of TB infection control
Implement and monitor World Health
Organization-recommended guidelines; monitor
rates of TB in health workers
Diagnose and treat drug-resistant TB Poor linkage to care; continued use of
inefficient CDST systems at national
laboratories; long duration of therapy
Monitor and improve linkage to care; prioritize
and plan for more efficient use of Xpert MTB/RIF;
aim for short 9- to 12-month multidrug-resistant
TB treatment; keep abreast of new diagnostic
molecular technology
Diagnose and treat HIV infection and
diabetes mellitus
HIV and diabetes increase TB mortality;
suboptimal uptake of HIV testing, ART, and
CPT; limited screening of TB patients for
diabetes
Aim for 100% uptake of HIV interventions; scale
up screening of TB patients for diabetes and
provide optimal diabetes care during anti-TB
treatment
ACF and treatment of LTBI Poor programmatic implementation of ACF
and treatment of LTBI
Design and implement strategies with particular
focus on people living with HIV and household
contacts
Engage with private-for-profit sector Poor implementation of the PPM strategy Focus on ways to improve the PPM strategy,
especially in Asia
Empower and strengthen central
units of TB Programs
Weak central units More focus on data-driven supportive
supervision, operational research, and sustained
financing

ACF, active case finding; ART, antiretroviral therapy; CDST, culture and drug susceptibility testing; CPT, cotrimoxazole preventive therapy; LTBI, latent tuberculosis infection; MTB, Mycobacterium tuberculosis; PPM, public-private mix; TB, tuberculosis.